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Maamoura Chest HospitalAbstract Background: Chronic obstructive pulmonary disease (COPD) is an important cause of
morbidity and mortality worldwide. However, it is often under diagnosed and under treated, result-
ing in underestimation of the burden of this disease. COPD is deﬁned as a preventable and treatable
disease with some signiﬁcant extra pulmonary effects that may contribute to the severity in individ-
ual patients. Its pulmonary component is characterized by airﬂow limitation that is not fully rever-
sible. The airﬂow limitation is usually progressive and associated with an abnormal inﬂammatory
response of the lung to noxious particles or gases.
Objective: To review the COPD cases who were admitted at Maamoura Chest Hospital during
the period from 2009 to 2012 as regards distribution of the disease, risk factors of the disease, sever-
ity and complications of the disease.
Patients and methods: This was a retrospective study that was based upon collecting the data of
all COPD patients who were admitted at Maamoura Chest Hospital during the period from 2009
till 2012. The data included the following: personal data, clinical data, methods of diagnosis, inten-
sive care unit admission, management and morbidity and mortality.
Results: In the present study, 77.3% of the patients’ age ranged between 35 and 70 years, 11.4%
were <35 years and 11.3% were >70 years. Also, 97.4% were males and 2.6% were females,
75.6% lived in urban areas and 24.4% lived in rural areas. 86.5% of the studied cases were smokers
and 13.5% were non smokers. 12.8% of the studied cases were addicts and 87.2% were not. 57.1%
of the addicted persons were addicted to cannabis, 19% were intravenous addicts and 23.8% were
addicts to tramadol. The most common co morbidities in COPD patients were respiratory infec-
tions in 53.9% of cases, heart failure in 44.5% of cases, IHD in 37.9% of cases, AF in 30.5% ofrculosis.
50 L.A. Helala et al.cases, HTN in 26.9% of cases and DM in 19.5% of cases respectively. The overall mortality rate
was 5.7%, 8.5% among the patients who received O2 therapy, 85.1% among the patients who were
put on CPAP, 63.8% among the patients who were put on invasive mechanical ventilation and
44.7% among the patients who were admitted to the ICU.
Conclusions: COPD is a very dangerous disease that affects the lives of many people. The overall
aim of management of stable COPD is to ensure good control of symptoms, to slow down the pro-
gression of the disease and to prevent further deterioration or complications. The sooner the diag-
nosis is made and interventions implemented, the more the long-term prognosis is improved.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
COPD is a common preventable and treatable disease is char-
acterized by persistent airﬂow limitation that is usually pro-
gressive and associated with an enhanced chronic
inﬂammatory response in the airways and the lung to noxious
particles or gases [1].
Exacerbations and co morbidities contribute to the overall
severity in individual patients. Chronic obstructive pulmonary
disease (COPD) is an important cause of morbidity and mor-
tality worldwide. However, it is often under diagnosed and
under treated, resulting in underestimation of the burden of
this disease [2].
COPD is deﬁned as a preventable and treatable disease with
some signiﬁcant extra pulmonary effects that may contribute
to the severity in individual patients. Its pulmonary component
is characterized by airﬂow limitation that is not fully reversi-
ble. The airﬂow limitation is usually progressive and associated
with an abnormal inﬂammatory response of the lung to nox-
ious particles or gases [3].
COPD is a disease state characterized by airﬂow limitation
that is not fully reversible, the airﬂow limitation is usually both
progressive and associated with an abnormal inﬂammatory
response of the lungs to noxious particles or gases and associ-
ated with systemic manifestations [4].
The burden of COPD is underestimated because it is not
usually recognized and diagnosed until it is clinically apparent
and moderately advanced. Prevalence, morbidity, and mortal-
ity in Egypt are still lacking and have to be estimated, however,
COPD is a signiﬁcant health problem in both men and women.
The economic costs of COPD are high and will continue to rise
in direct relation to the ever-aging population, the increasing
prevalence of the disease, and the cost of new and existing
medical and public health interventions [1].
Morbidity measures traditionally include physician visits,
emergency department visits, and hospitalizations. Although
CORD databases for these outcome parameters are less readily
available and usually less reliable than mortality databases, the
limited data available indicate that morbidity due to CORD
increases with age [5,6]. Morbidity from COPD may be
affected by other co morbid chronic conditions (e.g. cardiovas-
cular disease, musculoskeletal impairment, and diabetes melli-
tus) that are related to CORD and may have an impact on the
patient’s health status, as well as interfere with COPD
management.
The age-adjusted death rates for COPD by race and sex in
the US from 1960 to 1996 revealed that COPD death rates are
very low among people under age 45, but then increase withage, and COPD becomes the fourth or ﬁfth leading cause of
death among those over 45 years, a pattern that reﬂects the
cumulative effect of cigarette smoking [7].
Observed increases in mortality and morbidity appear to be
related to past trends in cigarette smoking. Part of the rise in
morbidity and mortality may be due to increasing numbers
of people living longer, the increases in morbidity and mortal-
ity are particularly staking among older people who continue
to smoke [8].
Patients and methods
This was a retrospective study that was based upon collecting
the data of all COPD patients who were admitted at
Maamoura Chest Hospital during the period from 2009 till
2012. The data included the following:
(1) Personal data (age, sex, occupation, residence, special
habits {smoking and addiction}.
(2) Clinical data (symptoms, signs, frequency of exacerba-
tions, complications).
(3) Methods of diagnosis (clinically, spirometric function
test).
(4) ICU admission.
(5) Management either pharmacological medications or
non-pharmacological treatment e.g. rehabilitation pro-
gram, oxygen therapy and pneumococcal or inﬂuenza
vaccine).
(6) Morbidity and mortality.
Statistical analysis of the data
Data were fed to the computer and analyzed using IBM SPSS
software package version 20.0. Qualitative data were described
using number and percent. Quantitative data were described
using mean, standard deviation minimum and maximum.
Comparison between different groups regarding categorical
variables was tested using Chi-square test. Signiﬁcance test
results are quoted as two-tailed probabilities. Signiﬁcance of
the obtained results was judged at the 5% level.Results
Table 1 shows that 77.3% of the patients’ age ranged between
35 and 70 years, 11.4% of them were <35 years and 11.3%
were >70 years. Regarding the sex of the patients, 97.4% of
Table 1 Distribution of studied cases according to demo-
graphic data (n= 1637).
No. %
Age
<35 186 11.4
35–70 1266 77.3
>70 185 11.3
Sex
Male 1595 97.4
Female 42 2.6
Residence
Rural 400 24.4
Urban 1237 75.6
Occupation
No work-retired 961 58.7
Manual worker 637 38.9
Oﬃce worker 39 2.4
Negative 
1543
94.3%
Positive
94
5.7%
Figure 1 Mortality rate among the studied cases.
Table 2 Distribution of studied cases according to manual
working (n= 637).
No. %
Inorganic dust exposure 300 47.1
Silica dust exposure 140 22.0
Asbestos dust exposure 70 11.0
Coal dust exposure 90 14.1
Organic dust exposure 71 11.1
Chemicals, irritant gases’ exposure 266 41.8
Table 3 Distribution of studied cases according to addiction
habits (n= 1637).
No. %
Drug addiction
Negative 1427 87.2
Positive 210 12.8
Cannabis addiction 120 57.1
IV addiction 40 19.1
Tramadol addiction 50 23.8
Table 4 Distribution of studied cases according to smoking
habits (n= 1637).
No. %
Smoking
Non smoker 221 13.5
Smoker 1416 86.5
Smoking index
Mild 271 19.2
Moderate 544 38.4
Heavy 601 42.4
Min.–Max. 5.0–80.0
Mean ± SD. 21.89 ± 15.92
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dence, 75.6% of the patients lived in urban areas and 24.4%
lived in rural areas. By looking at the occupation, 58.7% were
not working, 38.9% were manual workers and 2.4% were
ofﬁce workers (see Fig. 1).
Table 2 shows that 47.1% of the manual workers were
exposed to inorganic dust (22% of them were exposed to silica
dust, 11% were exposed to asbestos ﬁbers and 14.1% were
exposed to coal dust), 11.1% of them were exposed to organic
dust and 41.8% were exposed to other chemicals and irritant
gases.
Table 3 shows that 12.8% of the patients were addicts and
87.2% of them were none. As regards the addict group, 57.1%
of them were addict to cannabis, 19.1% of them were intra-
venous addicts and 23.8% were addict to tramadol.
Table 4 shows that 86.5% of the patients were smokers and
13.5% were non smokers. In the smoking group, 19.2% were
mild smokers, 38.4% were moderate smokers and 42.4% were
heavy smokers according to smoking index with a mean ± SD
21.89 ± 15.92.
Table 5 shows that 40.6% of the cases were complaining of
dyspnea Grade III, 38.4% of them were complaining of dysp-
nea Grade II, while 14.8% were complaining of dyspnea
Grade I and 6.2% were complaining of dyspnea Grade VI.
In addition, 77.3% of the patients were complaining of pro-
ductive cough and 22.7% were complaining of dry cough.
Also, 86.7% of the patients were complaining of wheezes
and 13.3% of the cases had silent chest.
Table 6 shows that frequency of exacerbation/year was 4
episodes/year in 29% of the patients, 5 episodes/year in
26.1% of the patients, 3 episodes/year in 11.8% of the patients,
2 episodes/year in 10.8% of the patients, once/year in 9.4% of
the patients, 8 episodes/year in 5.4% of the patients, 6 episo-
des/year in 4.5% of the patients, 10 episodes/year in 2.3% of
the patients and 12 episodes/year in 0.7% of the patients
respectively.
Table 7 shows that the most common co morbidities in the
patients were respiratory infections (53.9%), heart failure
(44.5%), IHD (37.9%), AF (30.5%), HTN (26.9%) and DM
(19.5%) respectively.Table 8 shows that the most common complications in the
studied patients were corpulmonale in 44.5% of cases, respira-
tory failure type 2 in 16.6% of cases, secondary polycythemia
in 15.1% of cases, pneumothorax in 10.7% of cases, lung can-
cer in 12.2% of cases and complications due to medications
Table 5 Distribution of studied cases according to symptoms
(n= 1637).
No. %
Dyspnea grades
Grade I 242 14.8
Grade II 628 38.4
Grade III 665 40.6
Grade VI 102 6.2
Cough
Dry 371 22.7
Productive 1266 77.3
Wheezes
Silent chest 218 13.3
Positive 1419 86.7
Table 6 Distribution of the studied cases according to
frequency of exacerbation/year (n= 1637).
No. %
Frequency of exacerbation/year
1 154 9.4
2 176 10.8
3 193 11.8
4 474 29.0
5 428 26.1
6 74 4.5
8 89 5.4
10 37 2.3
12 12 0.7
Table 7 Distribution of studied cases according to other co
morbidities (n= 1637).
No. %
IHD 620 37.9
HTN 440 26.9
DM 320 19.5
Heart failure 728 44.5
Respiratory infection 883 53.9
AF 500 30.5
Table 8 Distribution of studied cases according to the
complications of the disease (n= 1637).
No. %
RF ‘‘type II’’
Negative 1365 83.4
Positive 272 16.6
Corpulmonale
Negative 909 55.5
Positive 728 44.5
Pneumothorax
Negative 1462 89.3
Positive 175 10.7
Lung cancer
Negative 1437 87.8
Positive 200 12.2
Secondary polycythemia
Negative 1389 84.9
Positive 248 15.1
Complication due to medications
DM 670 40.9
HTN 858 52.4
IHD 447 27.3
Gastritis 200 12.2
Osteoporosis 10 0.6
Anxiety, irritability 50 3.1
Table 9 Distribution of studied cases according to ICU
admission (n= 1637).
No. %
ICU admission
Negative 1119 68.4
Positive 518 31.6
Table 10 Relation between ICU admission and
complications.
ICU admission v2 P
Negative
(n= 1119)
Positive
(n= 518)
No. % No. %
RF ‘‘type II’’ 8 2.9 264 97.1 645.334* <0.001*
Corpulmonale 388 53.3 340 46.7 137.469* <0.001*
Pneumothorax 160 91.4 15 8.6 48.221* <0.001*
Lung cancer 139 69.5 61 30.5 0.138 0.771
Secondary
polycythemia
52 21.0 196 79.0 303.453* <0.001*
v2: Chi square test.
* Statistically signiﬁcant at p 6 0.05.
52 L.A. Helala et al.including DM in 40.9% of cases, HTN in 52.4% of cases, IHD
in 27.3% of cases, gastritis in 12.2% of cases, osteoporosis in
0.6% of cases and anxiety and irritability in 3.1% of cases.
Table 9 shows that 31.6% of the studied cases were admit-
ted to the ICU and 68.4% of them were not.
Table 10 shows that there was a highly signiﬁcant relation
between the presence of respiratory failure type II, corpul-
monale and secondary polycythemia and the need for ICU
admission, but this relation was not signiﬁcant as regards the
presence of pneumothorax and lung cancer.
Table 11 shows that the studied cases had FEV1 ranging
from 28.0% to 67.0% with a mean of 45.75 ± 8.19. Only
89.2% of the cases had done PFT and 10.8% did not perform
PFT.Table 12 shows that there was a signiﬁcant relation between
the smoking index and the increase in the level of obstruction
i.e. disease severity (expressed by decreased FEV1/FVC ratio).
Also, there was a highly signiﬁcant inverse correlation between
Table 11 Distribution of studied cases according to FEV1/
FVC (FEV1) (n= 1637).
No. %
FEV1/FVC (FEV1)
Negative 176 10.8
Positive 1461 89.2
Min.–Max. 28.0–67.0
Mean ± S.D. 45.75 ± 8.19
Table 13 Distribution of the studied cases according to
pharmacological treatment (n= 1637).
Negative Positive
No. % No. %
ICS 103 6.3 1534 93.7
SABA 151 9.2 1486 90.8
LABA 149 9.1 1488 90.9
Anticholinergics 188 11.5 1449 88.5
SYS CST 791 48.3 846 51.7
Theophylline 362 22.1 1275 77.9
Antibiotics 151 9.2 1486 90.8
Mucolytics 46 2.8 1591 97.2
Table 14 Distribution of the studied cases according to non
pharmacological treatment.
No. %
Pulmonary rehabilitation
Negative 728 44.5
Positive 909 55.5
O2 therapy
Negative 269 16.4
Positive 1368 83.6
Non invasive mechanical ventilation(CPAP)
Negative 1320 80.6
Positive 317 19.4
Invasive mechanical ventilation
Negative 1442 88.1
Positive 195 11.9
Pneumococcal/inﬂuenza vaccine
Negative 1603 97.9
Positive 34 2.1
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increases, the FEV1/FVC% decreases.
Table 13 shows that 93.7% of the studied cases used
inhaled corticosteroids (ICS), 90.9% used long acting B2 ago-
nist (LABA), 90.8% used short acting B2 agonist (SABA),
97.2% used mucolytics, 90.8% used broad spectrum antibi-
otics, 88.5% used anticholinergics, 77.9% used theophylline
and 51.7% used systemic corticosteroids.
Table 14 shows that 55.5% of the studied cases received
pulmonary rehabilitation, 19.4% were put on CPAP, 83.6%
received O2 therapy, 11.9% were put on invasive mechanical
ventilation and 2.1% received pneumococcal vaccine.
Table 15 shows that there was a highly signiﬁcant relation
between the presence of respiratory failure type 2, corpul-
monale, pneumothorax, lung cancer and polycythemia as com-
plications of COPD and the need for O2 therapy.
Table 16 shows that there was a highly signiﬁcant relation
between the presence of respiratory failure type II and the need
for CPAP, but this relation was not signiﬁcant with the pres-
ence of other complications.
Table 17 shows that there was no signiﬁcant relation
between the presence of the different complications of COPD
and the need for invasive mechanical ventilation.
Table 18 shows that the overall mortality rate among the
studied cases was 5.7%.
Table 19 shows that the mortality rate among the patients
who received O2 therapy was 8.5%.
Table 20 shows that the mortality rate among the patients
who were put on CPAP was 85.1%.
Table 21 shows that the mortality rate among the patients
who were put on invasive mechanical ventilation was 63.8%.Table 12 Relation between FEV1/FVC ratio and smoking index.
Mild (n= 255) Moderate (n= 473
FEV1/FVC (FEV1)
Min.–Max. 30.20–67.0 30.20–67.0
Mean ± SD. 46.91 ± 8.37 45.59 ± 7.54
Median 45.0 45.3
Pairwise comp. II–III***
F: F test (ANOVA).
Pairwise comparison was done using post hoc test (Scheffe).
I: Mild smoking index.
II: Moderate smoking index.
III: Heavy smoking index.
* Statistically signiﬁcant at p 6 0.05.
*** Statistically signiﬁcant at p 6 0.001.Table 22 shows that the mortality rate among the patients
who were admitted to the ICU was 44.7%.) Heavy (n= 540) F P
28.20–65.0 11.091* <0.001*
44.53 ± 7.95
43.0
Table 22 Relation between mortality and ICU stay.
Mortality v2 P
Negative
(n= 1543)
Positive
(n= 94)
No. % No. %
ICU stay
Negative 1067 69.2 52 55.3 7.837* 0.005*
Positive 476 30.8 42 44.7
v2: Chi square test.
* Statistically signiﬁcant at p 6 0.05.
Table 15 Relation between O2 therapy and complications.
O2 therapy v
2 P
Negative
(n= 269)
Positive
(n= 1368)
No. % No. %
RF ‘‘type II’’ 112 41.2 160 58.8 863.447* <0.001*
Corpulmonale 167 22.9 561 77.1 213.236* <0.001*
Pneumothorax 35 20.0 140 80.0 63.000* <0.001*
Lung cancer 31 15.5 169 84.5 95.220* <0.001*
Polycythemia 67 27.0 181 73.0 52.403* <0.001*
v2: Chi square test.
* Statistically signiﬁcant at p 6 0.05.
Table 16 Relation between CPAP and complications.
CPAP v2 P
Negative
(n= 1320)
Positive
(n= 317)
No. % No. %
RF ‘‘type II’’ 132 48.6 140 51.4 215.337* <0.001*
Corpulmonale 535 73.5 193 26.5 42.879* <0.001*
Lung cancer 162 81.0 38 19.0 0.019 0.889
Polycythemia 185 74.6 63 25.4 6.825* 0.009*
v2: Chi square test.
* Statistically signiﬁcant at p 6 0.05.
Table 17 Relation between invasive mechanical ventilation
and complications.
Invasive mechanical
ventilation
v2 P
Negative
(n= 1442)
Positive
(n= 195)
No. % No. %
RF ‘‘type II’’ 140 51.5 132 48.5 416.828* <0.001*
Corpulmonale 696 95.6 32 4.4 70.598* <0.001*
Pneumothorax 171 97.7 4 2.3 4.435* 0.035*
Lung cancer 188 94.0 12 6.0 7.589* 0.006
Polycythemia 238 96.0 10 4.0 17.295* 0.195
v2: Chi square test.
* Statistically signiﬁcant at p 6 0.05.
Table 18 Mortality rate among the studied cases (n= 1637).
No. %
Mortality
Negative 1543 94.3
Positive 94 5.7
Table 19 Relation between O2 therapy and mortality.
O2 therapy v
2 P
Negative
(n= 269)
Positive
(n= 1368)
No. % No. %
Mortality
Negative 183 11.9 1360 88.1 409.120* <0.001*
Positive 86 91.5 8 8.5
v2: Chi square test.
* Statistically signiﬁcant at p 6 0.05.
Table 20 Relation between CPAP and mortality.
CPAP v2 P
Negative
(n= 1320)
Positive
(n= 317)
No. % No. %
Mortality
Negative 1306 84.6 237 15.4 276.030* <0.001*
Positive 14 14.9 80 85.1
v2: Chi square test.
* Statistically signiﬁcant at p 6 0.05.
Table 21 Relation between invasive mechanical ventilation
and mortality.
Invasive mechanical ventilation v2 P
Negative
(n= 1442)
Positive
(n= 195)
No. % No. %
Mortality
Negative 1408 91.3 135 8.7 256.177* <0.001*
Positive 34 36.2 60 63.8
v2: Chi square test.
* Statistically signiﬁcant at p 6 0.05.
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Chronic obstructive pulmonary disease (COPD) is a common
preventable and treatable disease, characterized by persistentairﬂow limitation that is usually progressive and associated
with an enhanced chronic inﬂammatory response in the air-
ways and the lung to noxious particles or gases.
Exacerbations and co morbidities contribute to the overall
severity in individual patients [1].
Review of chronic obstructive airway disease patients 55Age is often listed as a risk factor for COPD. It is unclear if
healthy aging as such leads to COPD or if age reﬂects the sum
of cumulative exposures throughout life. In the present study,
COPD was most common in the patients whose age ranged
between 35 and 70 years (77.3%), 11.4% of the patients were
under the age of 35 years and 11.3% of the patients were above
the age of 70 years. In accordance with this result, Hnizdo
et al. [9] found that patients aged 30–75 years estimated the
major fraction of COPD. Also, Higgins [10] reported that a
diagnosis of COPD should be considered in patients over the
age of 35 who have a risk factor (generally smoking).
Fletcher et al. [11] reported that while COPD is known to sig-
niﬁcantly impact older age groups, it also affects people of
working age. Recent data report that 26% of people with
COPD in the UK aged 45–65 gave up work because of their
condition, and of those having COPD remaining in work,
22.9% felt that it lowered their productivity. Different results
concluded by American Lung Association [12] found that
COPD is not common among populations under 45 years of
age. Halbert et al. [13] found that the majority of the studies
concerned patients over 40 years of age, in particular those
aged between 40 and 64 years. The prevalence of COPD
increases with age, with a ﬁvefold increased risk for those aged
over 65 yrs compared with patients aged less than 40 years.
As regards sex of the patients in our study, COPD was
more prevalent in males than in females; it included 97.4%
males and 2.6% female. This result is supported by the state-
ment of National Heart, Lung and Blood Institute [14] which
informed that COPD prevalence and mortality were greater
among men than among women. In addition, Bourke [15]
reported that there is a higher prevalence of COPD in men
than in women, where there is an increased incidence of man-
ual labor such as mining and welding, which carry an increased
risk of COPD. On the contrary to this result; Bill et al. [16]
found that COPD was more common in women than in
men. Hogg et al. [17] described that studies have shown that
women with COPD generally report more breathlessness,
depression and frequent exacerbations than men, even when
their FEV1 is the same. However; Mannino et al. [18] showed
that the prevalence of the disease is now almost equal in men
and women, probably reﬂecting the changing patterns of
tobacco smoking. Also, Viegi et al. [19] addressed the impor-
tant issue of a remarkably high incidence of COPD in the
youngest women, which suggests a further shift toward females
in the sex distribution of COPD. In conclusion, these recent
data from several large studies suggest that females may in fact
be more susceptible to the effects of tobacco than males. These
studies differ according to the number and place of subjects.
More data are needed to verify this. The importance of these
new data, however, is that male sex is now clearly not a risk
factor for COPD.
As regards the socioeconomic status, there is a higher inci-
dence of COPD in patients of lower socioeconomic status, par-
ticularly those living in urban rather than in rural areas. In the
present study, it was found that among the studied cases,
75.6% lived in urban areas and 24.4% lived in rural areas.
This pattern reﬂects exposures to indoor and outdoor air pol-
lutants, crowding, poor nutrition, infections, or other factors
that are related to low socioeconomic status. This result
matches with that reported by Prescott et al. [20] that stated
that poverty is clearly a risk factor for COPD and there is
strong evidence that the risk of developing COPD is inverselyrelated to socioeconomic status. They concluded that poverty
is an important surrogate of COPD. There is a higher inci-
dence of COPD in patients of lower socioeconomic status, par-
ticularly those living in urban rather than rural areas.
Tobacco smoking is the main risk factor for COPD. In our
study it was found that studied cases included 86.5% smokers
and13.5% non smokers. This result matches with that reported
by Agusti et al. [21], which found that Tobacco smoking is by
far the most important risk factor for COPD worldwide,
Siafakas et al. [22] also reported that smoking is the main risk
factor for the development of COPD. Overall, tobacco smok-
ing accounts for as much as 90% of COPD risk.
There is a direct relationship between the amount of cigar-
ettes and the number of years smoked, which is quantized in
terms of ‘pack years’. The formula used to determine this is
Number of cigarettes smoked per day · number of years
smoked/20 to form pack year index. In this current study,
according to this index, it was found that 19.1% of smokers
were mild smokers, 38.4% were moderate smokers and
42.4% were heavy smokers, with a mean 21.89 ± 15.92.
Similarly, American Collage of Chest Physicians/American
Thoracic Society/European Thoracic Society guidelines found
that the value of patient history and physical examination was
addressed in the 2011 update for diagnosis and management of
stable COPD. According to the 2011 guidelines, a history of
more than 40 pack- year of smoking was the best single predic-
tor of airﬂow obstruction.
In the present study, it was found that there is a signiﬁcant
relation between smoking index and the degree of disease
severity or level of decline of pulmonary functions. There
was a highly signiﬁcant inverse correlation found between
smoking in pack years and FEV1/FVC%, i.e. as the smoking
index increases, the FEV1/FVC% decreases. This result is sim-
ilar to those of early studies conducted by Fletcher et al. [23]
that stated that cigarette smoking accelerates the rate of
decline in FEV1, but it is thought that this may be greater in
the presence of airway hyper-responsiveness. Also, this result
agrees with those of the study of Tonnesen et al. [24], who
reported that people who smoke have an increased annual
decline in FEV1:the physiologic normal decline in FEV1 is
estimated to be 20–30 ml/y, but the rate of decline in COPD
patients is generally 60 ml/y or greater. Nagelmann et al. [25]
found that lung function deviation and lung structural changes
are present in people who smoke cigarettes before the clinical
signs of airways obstruction reveal them. These changes can
be detected by body plethysmography and diffusing capacity
measurement with routine spirometry.
As regards the occupation in this current study, it was
found that 47.1% of COPD patients were manual workers
who were exposed to inorganic dust, while 11.1% of them were
exposed to organic dust and 41.8% of them were exposed to
other chemicals and irritant gases. Among the group of man-
ual workers who were exposed to inorganic dust, 22% of them
were exposed to silica dust, 11% of them were exposed to cot-
ton dust and 14.1% of them were exposed to coal dust. This
result coincides with observations of Burge [26], that recorded
accelerated decline in lung function among plastics workers
exposed to toluene diisocyanate and in carding room workers
in cotton mills. Exposure to cadmium, a heavy metal, and
welding fumes has been recognized as a cause of emphysema
since the 1950s. Hnizdo et al. [27] found an increased number
of cases of chronic bronchitis in coal and gold miners,
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development of chronic bronchitis and emphysema. Bill et al.
[16] found that occupational dusts; organic and inorganic;
are attributable risks in 15% of American population.
Automobile-drivers, vehicular mechanics, chlorinated organic
compounds dyes, explosives, rubber products, metal etching,
plastics, ammonia exposure in refrigeration and petroleum
reﬁning, grain dust and funguses in farmers, textile mill man-
ufacturing, leather manufacturing, food products manufactur-
ing and sales, beauty care workers and welders in automotive
industries. Also, this result is consistent with the results of
Hendrick [28], who reported that shipyard welders and caulk-
ers are also known to have an increased risk of developing
COPD as well as those working in the construction industries
that are exposed to cement dust. Different results had been
reported by eauWyatt [29], who found that COPD is the most
common respiratory syndrome in agricultural workers, and
there is a 10% prevalence of COPD among farm workers.
Regarding addiction in the present study, it included
12.8%addicts and 87.2% non addicts. Also, it was found that
57.1% of the addicted persons were addicted to cannabis
including marijuana, 19% of them was intravenous addicts
and 23.8% addicts to tramadol. In accordance with this ﬁnd-
ing, Salvi and Barnes [30] found that other types of tobacco
e.g. pipe, cigar, water pipes and marijuana are also risk factors
for COPD. Nagelmann et al. [25] stated that emphysema
occurs in approximately 2% of persons who use intravenous
drugs. This is attributed to pulmonary vascular damage that
results from insoluble ﬁller (e.g. cornstarch, cotton ﬁbers, cel-
lulose and talc) that contained methadone or methylphenidate.
Lamprecht et al. [31] found that in association with IV use of
cocaine or heroin; emphysema occurs predominantly in the
upper lobes. In contrast, methadone and methylphenidate
injections are associated with basilar and panacinar emphy-
sema. Vilagoftis et al. [32] said that it is worth mentioning that
marijuana (cannabis) may be a major cause of COPD for the
future. Although marijuana cigarettes are not smoked as often
as nicotine cigarettes, marijuana smoking involves a larger vol-
ume a longer breath hold. The result of the present study dis-
agrees with those of Tashkin et al. [33]; who had done various
studies suggesting that marijuana smoking may not affect an
accelerated reduction in FEV1. However, a study by
Johnson et al. [34] reported a bullous lung disease in young
adults who had smoked marijuana.
In this current study, it was found that frequency of exacer-
bation/year in COPD patients was 4 episodes/year in 29% of
patients, 5 episodes/year in 26.1% of patients, 3 episodes/year
in 11.8% of patients, 2 episodes/year in 10.8% of patients,
once/year in 9.4% of patients, 8 episodes/year in 5.4% of
patients, 6 episodes/year in 4.5% of patients 10 episodes/year
in 2.3% of patients and 12 episodes/year in 0.7% of patients
respectively. Different results had been reported by Davis
et al. [35] and Barnett [36] showed that the average district gen-
eral hospital will receive between 1000 and 1200 admissions a
year, with a mean stay of 10.3 days.
In this current study, as regards cough, it was found that
77.3% of the patients were complaining of productive cough
and 22.7% complaining of dry cough. These ﬁndings were sim-
ilar to those of Georgopoulas and Anthonisen [37], who found
that chronic cough is usually productive and is very often dis-
counted as it is considered an expected consequence of smok-
ing. Also, this matches with that reported by Burrows et al.[38], who stated that sputum initially occurs in the morning
but later will be present all day long. It is usually tenacious.
The chronic cough in COPD may be unproductive. Robin
et al. [39] showed that one of the ﬁrst signs of COPD is a per-
sistent productive cough that is often worse in the morning.
Contrary to this result, Anthonisen [40] found that in some
cases of COPD, signiﬁcant airﬂow limitation may develop
without the presence of a cough.
In this current study, it was found that 40.6% of the cases
were complaining of dyspnea Grade III, 38.4% Grade II,
14.8% Grade I and 6.2% Grade VI. In accordance with our
study, Simon et al. [41] and Elliott et al. [42] reported that typ-
ical COPD patients describe their dyspnea as a sense of
increased effort to breathe, heaviness, air hunger, or gasping.
However, the terms used to describe dyspnea vary both by
individual and by culture. In a study done by Graham Barr
et al. [43] among 1003 patients with COPD, 61%reported
moderate or severe dyspnea. Different results reported by
Nishimura et al. [44], who studied 183 COPD patients. They
found that 67 patients (36%) were classiﬁed with Grade II,
87 patients (48%) were classiﬁed with Grade III, 26 patients
(14%) were classiﬁed with Grade IV and 3 patients (2%) were
classiﬁed with Grade V. This difference may be due to the fact
that this study included a small number of patients.
In this current study, it was found that 90% of the patients
were complaining of wheezes and 10% of cases have silent
chest. On the contrary, Schols et al. [45] stated wheezing and
chest tightness are nonspeciﬁc symptoms that may vary
between days and over the course of a single day.
Alternatively, widespread inspiratory or expiratory wheezes
can be present on listening to the chest.
COPD often coexists with other disease. (Co morbidities)
that may have a signiﬁcant impact on prognosis. It is increas-
ingly recognized that many patients with COPD have co mor-
bidities that have a major impact on quality of life and
survival. Co morbidities are common at any severity of
COPD [46].
The current study revealed that the most common co mor-
bidities in COPD patients were respiratory infections (53.9%),
heart failure (44.5%), IHD (37.9%), AF (30.5%), HTN
(26.9%) and DM (19.5%) respectively. In accordance with
our study, Benﬁeld et al. [47] found that serious infections,
especially respiratory infections, are the most frequently seen
in patients with COPD. Soriano et al. [48] and Fabbri et al.
[49] reported that CVD is a major co morbidity in COPD, 4
separate entities within CVD will be considered: ischemic heart
disease, heart failure, atrial ﬁbrillation and hypertension. On
the contrary, Mikkelsen [50]. found that COPD is a disease
with multiple co-morbidities and the most common co-
morbidities of COPD are anxiety and depression. Fabbri
et al. [49] reported that Hypertension is likely to be the most
frequently occurring co morbidity in COPD and has implica-
tions on prognosis. Also, there is a different result concluded
by Rubinsztajn and Chazan [51] in their study of hospitalized
observed COPD patients from the national hospital discharge
survey, in the United States from 1979 to 2001. They reported
that the most common co morbidities were pneumonia, hyper-
tension, diabetes, heart failure, ischemic heart disease, pul-
monary vascular disease, thoracic malignancy and
respiratory failure respectively. Soriano et al. [48] in their study
of COPD patients (n= 2699) reported that the most common
co morbidities were pneumonia, osteoporosis, respiratory
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coma and cataract. In a study done by Graham Barr et al. [43]
among 1003 patients with COPD, the most prevalent co mor-
bid diseases were hypertension (55%), hypercholesterolemia
(52%), depression (37%), cataracts (31%) and osteoporosis
(28%). This difference between the present study and the
above listed ones may be related to difference in the numbers
of enrolled patients in each study and the difference in the
communities in which the studies were conducted.
In the present study it was found that the most common
complications in COPD patients were corpulmonale (44.5%),
respiratory failure type II (16.6%), secondary polycythemia
(15.1%), pneumothorax (10.7%), lung cancer (12.2%) and
complications due to medications including DM (40.9%),
HTN (52.4%), IHD (27.3%), Gastritis (12.2%), lung cancer
(12.2%), osteoporosis (0.6%) and anxiety, irritability (3.1%).
This matches with the study conducted by Mannino et al.
[52] that shows that the presence of metabolic syndrome and
manifest diabetes are more frequent in COPD.
Spirometry is the gold standard for COPD and is the only
accurate method of measuring the degree of airﬂow obstruc-
tion in patients with COPD; it should be used in conjunction
with a good history and physical examination. A diagnosis
of airﬂow obstruction can be made if FEV1/FVC <70%
and FEV1 <80% predicted normal values. In the present
study, it was found that the studied cases had FEV1/FVC ran-
ged from 30.2% 67.0 with a mean of 46.49 ± 8.14. So,
according to GOLD guidelines, these studied cases were classi-
ﬁed between moderate to severe COPD. This result differs
from those reported by Steuten et al. [53], who studied 317
patients with COPD according to GOLD guidelines, 29% of
the patients had mild COPD, 48% moderate, 17% severe
and 5% very severe. Also, in a study done by Stahl et al.
[54] who enrolled 168 subjects with COPD from a representa-
tive sample of the general population in the northern Sweden
using GOLD stages, it was found that FEV1/FVC was
>80% in 81 patients, 79–50% in 68 patients and 49–30% in
10 patients and no patient had a value less than 30%. This dif-
ference may be related to the smaller number of patients in the
previous studies and the different communities where the stud-
ies were conducted upon.
As regards bronchodilators pharmacotherapy in the present
study, it was found that 90.9% of our studied cases used long
acting B2 agonists (LABA), 90.7% used short acting B2 ago-
nists (SABA). In accordance with our study ERS/ATS guide-
lines [55] and Hay and Stone [56] stated that short-acting
bronchodilators can increase exercise capacity in COPD
patients and are indicated for acute symptom control and
treatment of exacerbation. Unlike short-acting b2 agonists,
long-acting b2 agonists should not be used to control symp-
toms or to treat exacerbations (i.e. as a rescue medication)
but are intended for maintenance therapy. As regards anti-
cholinergics, 88.5% of our studied cases used anticholinergics.
This is partially similar to the study of Sheldon et al. [57] which
stated that anticholinergics appear more useful in the relief of
symptoms in older patients or those with severe disease and a
heavy smoking history.
In this current study, it was found that 77.9% of the studied
cases used theophylline. Controversy remains about the exact
effects of xanthine derivatives. They may act as non selective
phosphodiesterase inhibitors, but have also been reported to
have a range of non-bronchodilator actions, the signiﬁcanceof which is disputed [58]. Vassallo et al. [59] stated that
Theophylline can be used as a third-line treatment in patients.
The mechanism of action remains uncertain but their mode of
action is thought to induce relaxation of the smooth muscle in
the airways.
As regards corticosteroids, 93.7% of our studied cases used
inhaled corticosteroids. Similarly, Spencer et al. [60] found that
regular treatment with inhaled corticosteroids improves symp-
toms, lung function, quality of life, and reduces the frequency
of exacerbations in COPD. Also, Sin et al. [61] study included
randomized controlled trials that had follow up group of
patients from 1980 to 2002 evaluating high value of use of long
acting bronchodilators and inhaled corticosteroids in reducing
exacerbations in patients with moderate to severe COPD .On
the other hand, Singh et al. [62] and Yang et al. [63] found that
regular treatment with inhaled corticosteroids does not modify
the long- term decline of FEV1 nor mortality in patients with
COPD. Corticosteroids can produce a small increase in post
bronchodilator FEV1 and a small reduction in bronchial reac-
tivity in stable COPD. This difference may be attributed to the
different number of enrolled patients in each study and differ-
ence in the community where the studies were conducted.
As regards antibiotics in this current study, 90.8% of the
studied cases used broad spectrum antibiotics This is in con-
trast to what was concluded by Francis et al. [64] and
Fletcher et al. [65], who stated that continuous use of antibi-
otics was shown to have no effect on the frequency of exacer-
bations in COPD.
Regarding mucolytics, 90.8% of our subject studies used
mucolytics. The regular use of mucolytics in COPD has been
evaluated in a number of long- term studies with controversial
results. National Institute for Clinical Excellence (NICE) [66]
and Celli and MacNee [67], showed that although a few
patients with viscous sputum may beneﬁt from mucolytics,
the overall beneﬁts seem to be very small.
Regarding non pharmacological treatment in the present
study, it was found that 72.8% received pulmonary rehabilita-
tion. The principal goals of pulmonary rehabilitation are to
reduce symptoms, improve quality of life, and increase physi-
cal and emotional participation in everyday activities.
[68,69]. This result matches with that reported by ERS/ATS
guidelines [55] which stated that pulmonary rehabilitation is
a multidisciplinary program that is individually tailored and
designed to optimize each patient’s physical performance and
psychological wellbeing.
In the present study, it was found that only 2.1% received
pneumococcal vaccine. This matches with the study of Davis
[70] conducted upon 100 patients with COPD who received
pneumococcal vaccine but they found that there is no signiﬁ-
cance of pneumococcal vaccine in prevention of pneumonia.
On the contrary, Leech et al. [71] found that there is a high sig-
niﬁcance in prevention of pneumonia in 189 COPD patients,
though only one documented case of pneumococcal sepsis
occurred in a patient who received pneumococcal vaccine
and had pneumonia. Lee et al. [72] supported the value of
pneumococcal vaccine in COPD patients through a study of
16,074 subjects (average age of 65 years) in the period from
1997 to 1998 and identiﬁcation of pneumococcal pneumonia
and all pneumonia related hospitalization in the period before
and after vaccination. Similarly, Jackson et al. [73] and
Alfageme et al. [74] stated that pneumococcal polysaccharide
vaccine is recommended for COPD patients 65 years and
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conditions such as cardiac disease. In addition, this vaccine has
been shown to reduce the incidence of community- acquired
pneumonia in COPD patients younger than age 65 with an
FEV1 <40% predicted.
As regards O2 therapy in the acute setting (in the hospital),
there was a highly signiﬁcant relation between the presence of
respiratory failure type 2, corpulmonale, pneumothorax, lung
cancer and polycythemia as complications of COPD and the
need for O2 therapy. In accordance with our study,
ERS/ATS guidelines [55] stated that O2 therapy prevents tissue
hypoxia by maintaining arterial oxygen saturation (SaO2) at
>90%. Also, Stoller et al. [75] demonstrated the beneﬁts of
short duration, intermittent supplemental O2 in relief of
breathlessness. On the same path, Standiford [76] mentioned
that the primary goal of oxygen therapy is to maintain vital
organ function by ensuring adequate oxygen delivery. This is
achieved by increasing the baseline PaO2 to at least
60 mmHg (or SaO2 to at least 90%) at rest.
As regards assisted ventilation in the present study, 19.4%
of the patients were put on non invasive mechanical ventilation
(CPAP) and 11.9% were put on invasive mechanical ventila-
tion. Non-invasive ventilation (NIV) is increasingly used in
patients with stable very severe COPD [77]. There was a highly
signiﬁcant relation between the presence of respiratory failure
type II and the need for CPAP (51.4%), while this relation was
not signiﬁcant with the rest of complications. The above result
is supported by the study of Shiveraman et al. [78], which
showed that the mask of CPAP signiﬁcantly improved gas
exchange in seven patients with acute hypercapnic respiratory
failure. The NICE guidelines [79] recommend the use of NIV
as a treatment for chronic hypercapnic ventilatory failure in
selected patients. ERS/ATS guidelines [55] stated that non
invasive positive pressure ventilation (NPPV) should be
offered to patients with exacerbations when, after optimal
medical therapy and oxygenation, respiratory acidosis
(pH < 7.36) and or excessive breathlessness persist.
International Consensus Conferences in Intensive Care
Medicine [80] mentioned that mechanical ventilation, either
‘‘invasive’’ or’’ non-invasive’’, is not a therapy but it is a form
of life support until the cause underlying the acute respiratory
failure is reversed with medical therapy.
In this current study, the mortality rate among the patients
who were put on CPAP was 85.1%. This result does not match
with that of Conti et al. [81] and Plant et al. [82], who found
that one-year mortality was reported to be lower in patients
receiving NPPV for exacerbations of COPD, as compared to
both conventional mechanical ventilation and optimal medical
therapy alone. This difference might be due to the difference in
the number of the patients enrolled in each study, as well as,
the experience of the physicians about CPAP.
Regarding ICU admission, 31.6% of the cases were
admitted to the ICU and 68.4% of them were not. This is
partially similar with the ﬁnding of Skilbeck et al. [83]
who stated that in a recent study of patients with COPD
or lung cancer in the US Veterans Affairs Health System
found that patients with COPD were much more likely to
be admitted to an ICU, and have greater lengths of stay
in the ICU during their terminal hospitalization, than
patients with lung cancer. In the same study, signiﬁcant geo-
graphic variation in ICU utilization was found for patients
with COPD. Although variation in care may be inﬂuencedby many factors including availability, access and reimburse-
ment issues, such geographic variation suggests a lack of
consensus concerning the best approach to palliative and
end-of-life care for patients with COPD. In summary, there
are important opportunities for research and quality
improvement if better palliative and end-of-life care is to
be provided for patients with severe COPD.
As regards the burden of COPD, WHO [84] showed that
the burden of COPD continues to increase, with recent statis-
tics reporting that COPD affects the lives of 210 million people
and contributes to 5% of deaths globally. Further evidence
suggests that by 2030, COPD will become the 3rd leading
cause of death worldwide. In the present study, the overall
mortality rate among the studied patients was 5.7% and
8.5% among the patients who received O2 therapy, 63.8%
among the patients who were put on invasive mechanical ven-
tilation and 44.7% among the patients who were admitted to
the ICU. In accordance with our study, McGarvey et al. [85]
mentioned that COPD is the fourth leading cause of death in
the United States. In terms of COPD as the underlying cause
of death, absolute mortality rates for patients aged 25 years
or older were 77.3 deaths per 100,000 males and 56.0 deaths
per 100,000 overall. Internationally, overall mortality rates
from COPD vary markedly; it is more than 400 deaths per
100,000 populations in Japan. Also, Chapman et al. [86]
reported that COPD is the fourth leading cause of death in
the United States, affecting 32 million adults. It is also the
sixth leading cause of death worldwide. National Heart, lung,
and Blood institute [87] stated the age-adjusted death rates for
COPD by race and sex in the US from 1960 to 1996, revealed
that COPD death rates are very low among people under the
age of 45 years, but then increase with age, and COPD
becomes the fourth or ﬁfth leading cause of death among those
over 45 years, a pattern that reﬂects the cumulative effect of
cigarette smoking, and also, the seventh leading cause of
DALYs lost worldwide in 2030. In 2000, the WHO estimated
2.74 million deaths worldwide from COPD.
The International Bank for Reconstruction on and
Development/The World Bank reported in 1990, COPD
was ranked 12th as a burden of disease; by 2020 it is pro-
jected to rank 5th. More than 3 million COPD deaths will
occur in 2005.On the same side, Bourke [15] estimated that
the total deaths from COPD are projected to increase by
more than 30% in the next 10 years. It is a major cause
of morbidity and mortality. Worldwide, COPD causes about
3 million deaths each year. In the UK in 1999, the number
of deaths from COPD had risen to 32, 155 [88], which
relates to one in 20 of all deaths, making it the 5th leading
cause of death [89]. By the year 2020, COPD is expected to
be third in the rankings for the global impact of disease
scale [90]. In England and Wales, mortality appears to be
greater in urban areas, with a particularly strong association
with lower social class and poverty and higher smoking rates
in this group.Conclusions
1. If COPD cases are reduced, the quality of life for many
people will increase substantially. There will also be more
money available for healthcare that would have been
previously been spent toward COPD cases. The beneﬁts
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more day should go by without action being taken to pre-
vent this disease from taking hold of another life.
2. COPD poses a common, growing and signiﬁcant clinical
challenge for patients and clinicians’ expert knowledge
regarding diagnosis and management can enhance patients’
longevity and quality of life. Results of emerging studies
will likely lead to enhancement in current management
and new paradigms in managing patients with COPD.
Recommendations
1. Smoking cessation is the single most important interven-
tion to slow the rate of lung decline and reduce respira-
tory symptoms regardless of the severity of the patient’s
disease. The beneﬁt of smoking cessation on the natural
history of COPD is greater the earlier in the disease that
cessation is achieved.
2. Also, preventive care focuses on avoiding irritants that
can aggravate COPD. The most common ‘‘triggers’’
are smoking, second hand smoke, occupational fumes
and chemicals, indoor air pollution (e.g. cooking with
biomass fuels), outdoor air pollution, and infection.
3. Patient education also improves patient response to
exacerbations. Prospective end-of-life discussions help
patients understand advanced directives and therapies
at end-of-life. Smoking cessation should be encouraged
at each visit. The combination of pharmacologic and
psychosocial treatment for smoking cessation has been
shown to be superior to psychosocial treatment alone
in patients with COPD.
4. Disease management involves partnering with nurses
and respiratory therapists to assist in patient education
and compliance. Patients enrolled in pulmonary rehabil-
itation receive instruction in self.
5. Patients with COPD are at increased risk for complica-
tions from pulmonary infections (e.g. hospitalization,
increased use of antibiotics). Therefore, the CDC
Advisory Committee of Immunization Practices recom-
mends all patients receive pneumococcal polysaccharide
vaccine and yearly inﬂuenza vaccine.
6. Early outpatient pulmonary rehabilitation after hospi-
talization is safe and results in signiﬁcant improve-
ments in exercise capacity and health status at
3 months. There is a pressing need to develop drugs
that control symptoms and prevent the progression of
COPD. Some progress has been made and there are
several classes of drugs that are now in preclinical
and clinical development for use in patients with
COPD.
7. Longitudinal studies demonstrating the course of COPD
are needed in a variety of populations exposed to vari-
ous risk factors. Such studies would provide insight into
the pathogenesis of COPD, identify additional genetic
bases for COPD, and identify how genetic risk factors
interact with environmental risk factors in speciﬁc
patient populations. Factors that determine why some,
but not all, smokers develop COPD need to be
identiﬁed.8. While spirometry is recommended to assess and monitor
COPD, other measures need to be developed and evalu-
ated in clinical practice. Reproducible and inexpensive
exercise-testing methodologies (e.g. stair-climbing tests)
suitable for use in developing countries need to be eval-
uated and their use encouraged. Spirometers need to be
developed that can ensure economical and accurate per-
formance when a relatively untrained operator adminis-
ters the test.
9. Because COPD is not fully reversible and slowly pro-
gressive, it will become ever more important to identify
early cases as more effective therapies emerge.
Consensus on standard methods for detection and deﬁ-
nition of early disease needs to be developed. Data to
show whether or not screening spirometry is effective
in directing management decisions in COPD outcomes
are required.
10. The speciﬁc components of effective education for
patients with COPD need to be determined. It is not
known, for example, whether patients with COPD
should be given an individual management plan, or
whether these plans are effective in reducing health care
costs or improving the outcomes of exacerbations.
Developing and evaluating effective tools for physician
education concerning prevention, diagnosis, and man-
agement of COPD will be important in view of the
increasing public health problem presented by COPD.
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